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Objectives. Both results of the odor identiﬁcation and cardiac 123I-metaiodobenzylguanidine accumulation have been investigated
for their potential to enhance the detection of pathogenesis resembling that of Lewy body-related α-synucleinopathies in patients
clinically diagnosed as having idiopathic REM sleep behavior disorder. Methods. We performed both the Odor Stick Identiﬁcation
Test for Japanese and 123I-metaiodobenzylguanidine scintigraphy in 30 patients with idiopathic REM sleep behavior disorder,
38 patients with Parkinson’s disease, and 20 control subjects. Results. In idiopathic REM sleep behavior disorder, reduced odor
identiﬁcation score and an early or delayed heart to mediastinum ratio on 123I-metaiodobenzylguanidine were almost as severe as
in Parkinson’sdisease patients. Delayed cardiac 123I-metaiodobenzylguanidine uptake waseven moresevere in the idiopathicREM
sleep behavior disorder group than in the Parkinson’s disease group. Conclusions. Reduced cardiac 123I-metaiodobenzylguanidine
uptake, which is independent of parkinsonism,may be more closely associated with idiopathic REM sleep behavior disorder than
olfactory impairment.
1.Introduction
REM sleep behavior disorder (RBD) is characterized by
dream-enacting behaviors and unpleasant dreams and pre-
sents a risk for self-injury and harm to others due to
abnormalREMsleepduringwhich controlofmuscletonusis
lacking(REMsleepwithoutatonia)[1,2].RBDisaheteroge-
neous disease entity consisting of a variety of manifestations
[1].IdiopathicRBD(iRBD),which developsinmiddleageor
later and progresses chronically, in particular is a common
clinical manifestation of Lewy body-related syndrome and
is regarded as a clinical entity from the pathological aspect.
For example, it has been elucidated that iRBD is often
accompanied by soft motor signs, olfactory and color iden-
tiﬁcation deﬁcits, decreased cardiovascular and respiratory
changes between REM and NREM sleep, reduced cardiac
123I-metaiodobenzylguanidine (123I-MIBG) uptake, impair-
ment of visual memory and visuospatial construction on
neuropsychological testing, EEG slowing during wakefulness
orsleep,anddecreasedstrialdopaminergicinnervations,and
reduced presynaptic strial dopamine transporter binding on
SPECT or positron emission topography (PET) scans, which
are consideredasnonmotorsymptomsofParkinson’s disease
(PD) [3–5]. Furthermore, despite the limited number of
pathological reports on iRBD, the characteristics of iRBD
have been supported to have a close relationship with Lewy
body pathology [6]. Therefore, additional clinical features
that could distinguish iRBD with Lewy body-related α-
synucleinopathies from iRBD from other causes would be
helpful in clinical practice. Recently, an association between
loss of olfactory function and loss of cardiac noradrenergic
innervation in PD has been noted [7]. Moreover, both loss
of sense of smell and cardiac sympathetic denervation can
precede the onset of motor symptoms, suggesting that the
combination might provide a biomarker for the risk of Lewy
body disease [8].
In this study, by the combination of tests to detect odor
identiﬁcation [9] and to determine cardiac 123I-MIBG
cardiac uptake [4, 5] that were selected from among various
tests to examine nonmotor symptoms of PD, we investigated2 Parkinson’s Disease
Table 1: Clinical characteristics of patients in the iRBD, PD, and control groups.
iRBD PD Controls P value
Number of patients, (n)3 0 3 8 2 0—
Age, years 65.8 ±9.16 5 .4 ±9.26 2 .3 ±6.8 0.210a
Sex (male, %) 83.3 63.2 90.0 0.102c
Disease duration, years 5.7 ±8.84 .8 ±4.8 N/A 0.599b
MMSE (>24) 27.7 ±2.32 7 .9 ±1.92 8 .8 ±1.4 0.096a
Hoehn and Yahr stage N/A 2.4 ±0.8N / A N / A
UPDRS motor subset, score 0.6 ±1.01 4 .4 ±7.8 N/A 0.000b
LEU, mg/day N/A 238.6 ±261.9N / A N / A
Smoker,(%) 50.0 39.5 5.0 0.464c
OSIT-J, score 5.2 ±3.04 .4 ±2.41 0 .3 ±1.3 0.000a
123I-MIBG
Early H/M ratio 1.85 ±0.33 2.14 ±0.52 2.74 ±0.33 0.000a
Delayed H/M ratio 1.46 ±0.29 1.83 ±0.60 2.82 ±0.47 0.000a
Data are mean ± SD.
PD: Parkinson’s disease, iRBD: idiopathic REM sleep behavior disorder, OSAS: obstructive sleep apnea syndrome, MMSE: Mini-Mental State Examination,
UPDRS: Uniﬁed Parkinson’s Disease Rating Scale, LEU: daily levodopa-equivalent unit, OSIT-J: Odor Stick Identiﬁcation Test for Japanese, H/M: heart-to-
mediastinum,and 123I-MIBG: 123I-metaiodobenzylguanidine.
aP value was determined by one-way ANOVA.
bP value was determined by Mann-Whitney U test.
cChi-square test for categorical: PD versus iRBD.
if there was an association between olfaction and cardiac
123I-MIBG uptake in patients with iRBD and PD to evaluate
the correlation between results of these two tests and to
determine which would more enhance the detection of
pathogenesis resembling that of Lewy body-related α-
synucleinopathies in patients clinically diagnosed as having
iRBD.
2.Methods
2.1. Patient Selection. This study was performed in accor-
dance with the Declaration of Helsinki. Procedures were
approved by the Ethics Review Committee of Dokkyo
MedicalUniversity,andinformedconsentwasobtainedfrom
each subject. Subjects were 82 patients matched according to
age group: 30 had iRBD (iRBD group; 66.3 ± 5.7y e a r s ;2 5
males, 5 females), 38 had PD (PD group; 65.4 ±9.2y e a r s ;2 4
males,14females),and20hadobstructivesleepapnea(OSA)
without RBD (control group; 62.3 ± 6.8 years; 18 males, 2
females; pretreatment AHI = 38.5±31.3events/h)(T able1).
RBD and OSAS were deﬁned according to the International
Classiﬁcation of Sleep Disorders, second edition [2]. Exclu-
sion criteria were an abnormal neurologic examination in
subjects with iRBD and OSAS. PD patients fulﬁlled the
United Kingdom Parkinson’s Disease Society Brain Bank
criteria for idiopathic PD [10]. Parkinsonism was assessed
andclassiﬁedaccordingtotheHoehnandYahrstage[11]and
the motor subset of Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS-III), which was administered to the PD and iRBD
groups[12].ThemeanUPDRS-IIIscorewas14.4±7.8points
f o rP Dp a t i e n t sa n d0 .6 ± 1.0 points for the iRBD subjects.
There were two phenotypes of PD among the PD group:
tremor-dominant and postural instability gait diﬃculty-
(PIGD-)dominantbasedonUPDRScomponents.Themean
PIGDscorewasdeﬁnedasthesumofanindividual’sbaseline
falling, freezing, walking, gait, and postural stability scores
divided by 5. Patients were categorized as having tremor-
dominant PD if the ratio of the mean tremor score to the
mean PIGD score was 1.5 or higher and as having PIGD-
dominant PD if that ratio was 1.00 or lower [13]. According
to that categorization, 13 patients in the PD group were
placed in the tremor-dominant subgroup and 21 in PIGD-
dominant subgroup. For this particular study, all patients
with Mini-Mental State Examination (MMSE) scores <24
were excluded [14].
2.2. Polysomnographic Evaluation and Deﬁnition of iRBD.
Polysomnographic (PSG) monitoring included electroen-
cephalography (C3, C4, O1, and O2), electrooculography,
chin muscle electromyography (EMG), electrocardiography,
detection of airﬂow by thermistor, plethysmography for
ribcage and abdominal wall motion, oximetry for mea-
surement of arterial oxyhemoglobin saturation, detection
of changes in sleeping position, and bilateral EMG of the
tibialis anterior muscles. PSG monitoring was performed for
at least 8h. Sleep stages were manually scored according to
criteria of Rechtschaﬀen and Kales [15]. Apnea was deﬁned
astheabsenceofbreathingformorethan10s.Hypopneawas
deﬁned as a reduction of more than 50% in breathing; when
the reduction in breathing was less than 50%, more than 3%
oxygen desaturation or arousal for more than 10s was
deﬁned as hypopnea. The apnea-hypopnea index was calcu-
lated as the average of the total number of apnea and hypop-
nea episodes experienced per hour of sleep. For the iRBD
group, the presence of REM sleep without atonia was based
on EMG ﬁndings of excessive sustained or intermittent ele-
vationof submentalEMG toneorexcessive phasic submental
orlowerlimbEMG twitching accordingtotheICSD-2ed[2].Parkinson’s Disease 3
Table 2: Multiple regression analysis of OSIT-J related parameters for Parkinson’s disease (N = 38) and iRBD (N = 30).
PD iRBD
βa P value βa P value
Age −0.348 0.037 0.016 0.936
Sex 0.404 0.033 0.080 0.701
Disease duration, month 0.147 0.591 −0.314 0.377
MMSE (>24) 0.189 0.230 0.184 0.377
Hoehn and Yahr stage −0.013 0.940 N/A N/A
UPDRS motor subset 0.079 0.674 −0.153 0.517
Motor phenotype −0.239 0.177 N/A N/A
LEU 0.074 0.969 N/A N/A
Smokingatatus 0.007 0.798 −0.040 0.834
Delayed H/M ratio (123I-MIBG) 0.399 0.015 −0.274 0.183
R2b 0.493 0.184
iRBD: idiopathic REM sleep behavior disorder, PD: Parkinson’s disease, OSIT-J: Odor Stick Identiﬁcation Test for Japanese, MMSE: Mini-Mental State
Examination, UPDRS: Uniﬁed Parkinson’s Disease Rating Scale, LEU: daily levodopa-equivalent unit, H/M: heart-to-mediastinum, and 123I-MIBG: 123I-
metaiodobenzylguanidine.
aStandardized regression coeﬃcients.
bCoeﬃcient of determination.
Bold values indicate statisticallysigniﬁcant values. N/A: not aplicable.
2.3. Cardiac 123I-MIBG Scintigraphy. 123I-MIBG planar ima-
ges of the chest were obtained using a triple-headed gamma
camera (GCA-9300A-HG, Toshiba Co, Tokyo, Japan). 123I-
MIBG (Fujiﬁlm RI Pharma Co., Tokyo, Japan) accumula-
tions were recorded at the early (15min) and delayed phases
(4h). The heart-to-mediastum (H/M) ratio was calculated
by dividing the count density of the left ventricular region of
interest (ROI) by that of the mediastinal ROI [16–18]. None
of the subjects took medications that could inﬂuence the
123I-MIBG examination, and none had a history of cardiac
disease.
2.4. Odor Stick Identiﬁcation Test for Japanese (OSIT-J). The
Odor Stick Identiﬁcation Test for Japanese (OSIT-J) (Daiichi
Yakuhin, Co., Ltd., Tokyo, Japan) is composed of 12 diﬀerent
odorants familiar tothe Japanese population[9].All subjects
were free from other conditions that can aﬀect olfactory
function such as usage of certain medications, chronic nasal
infection, chronic sinonasal disease, head trauma, and abuse
of drugs or alcohol by medical history. Subjects with an
infection ofthe upperairways at the time of the investigation
were also not allowed to participate. OSIT-J was performed
as previously described. In this study, functional hyposmia
was deﬁned by an OSIT-J score ≤8[ 9].
2.5. Statistical Analysis. Values are expressed as mean ± SD.
Age, MMSE, OSIT-J scores and degrees of accumulation
based on the H/M ratio (early and delayed phase) in cardiac
muscle obtained were compared among the three groups by
the one-way analysis ofvariance (ANOVA)followed by post-
hoc Bonferroni correction. The Mann-Whitney U-test was
applied for statistical comparisons of disease duration and
scores of the motor subsets of the UPDRS between the iRBD
and PD groups. Group comparisons of the frequency of
genders and smokers were performed by the Chi-square test
forcategoricalvariables. ThecorrelationsofOSIT-Jandearly
or delayed 123I-MIBG uptake were assessed by the Spearman
correlation coeﬃcient for iRBD and PD. To explore the most
inﬂuential factor on the OSIT-J score, we included age, sex,
disease duration, MMSE, Hoehn and Yahr stage, UPDRS
motor subsets, motor phenotypes, levodopa-equivalent unit
(LEU), smoking status, and delayed 123I-MIBG uptake in
a multiple regression analysis for PD. Receiver operating
characteristic (ROC) curves were analyzed. The signiﬁcance
level was set at P<. 05. Statistical analyses were performed
with the Statistical Package for Social Science Software
(Graphpad Prism, San Diego, CA and SPSS II Windows Ver
11.0, Japan).
3.Results
A total of 30 iRBD patients (mean symptom duration: 5.7 ±
8.8), 38 PD patients, and 20 control subjects with a similar
age distribution were evaluated. Demographic information
is presented in Table 1. Interval between 123I-MIBG exami-
nations and OSIT-J was a mean of 72 days.
Cardiac 123I-MIBG accumulation based on H/M (early
phase,delayedphase)wassigniﬁcantlydecreasedintheiRBD
group(1.85±0.33,1.46±0.29)andthePDgroup(2.14±0.52,
1.83 ± 0.60) compared with the control group (2.74 ± 0.33,
2.82±0.47)(P<. 000).OSIT-Jscoresweresigniﬁcantlylower
in the iRBD group (5.2 ± 3.0) and the PD group (4.4 ± 2.4)
than in the control group (10.3 ± 1.3) (P<. 000) (Table 1).
A ss h o w ni nT a b l e2, results of multiple regression analysis
of OSIT-J-related parameters in patients with PD, which
included age, sex, disease duration, MMSE, Hoehn and
Yahr stage, UPDRS motor subset, motor phenotype, LEU,
smoking status, and delayed H/M ratio, showed that age, sex,
and delayed H/M ratio were the signiﬁcant factors in the
model for the OSIT-J score. There was a signiﬁcant positive
correlation between the OSIT-J score and delayed H/M ratio4 Parkinson’s Disease
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Figure1:(a)ROCanalysisoftheearlyordelayed H/Mratioandodoridentiﬁcationshowedanareaunderthecurveof0.96(95% CI = 0.92–
1.00, P = .000), 0.99 (95% CI = 0.96–1.00, P = .000), and 0.96 (95% CI = 0.91–1.00, P = .000) for iRBD. (b) ROC analysis of the early or
delayed H/M ratio and odor identiﬁcation showed an area under the curve of 0.84 (95% CI = 0.74–0.94, P = .000), 0.88 (95% CI = 0.79–
0.97, P = .000), and 0.98 (95% CI = 0.96–1.00,P = .000) for PD.
Table 3:SensitivityandspeciﬁcityofOSIT-Jandcardiac 123I-MIBG
scintigraphy.
OSIT-J score Early H/M ratio Delayed
H/M ratio
iRBD patients
(n = 30)
Cut-oﬀ 8.5 2.30 2.03
Sensitivity 90.0% 95.0% 95.0%
Speciﬁcity 83.3% 86.7% 96.7%
PD patients
(n = 38)
Cut-oﬀ 8.5 2.30 2.03
Sensitivity 90.0% 95.0% 95.0%
Speciﬁcity 92.1% 71.1% 71.1%
iRBD: idiopathic REM sleep behavior disorder, PD: Parkinson’s disease,
OSIT-J: Odor Stick Identiﬁcation Test for Japanese, 123I-MIBG: 123I-
metaiodobenzylguanidine, H/M: heart-to-mediastinum.
(r = 0.337, P = .039, Spearman’s correlation). On the
other hand, results of multiple regression analysis of OSIT-
J-related parameters in patients with iRBD, which included
age, sex, disease duration, MMSE, UPDRS motor subset,
smoking status, and delayed H/M ratio, showed that there
were no signiﬁcant factors in the model for the OSIT-J score.
Among the iRBD group, there was no signiﬁcant correlation
between the OSIT-J score and delayed H/M ratio (r =
−0.195, P = .302, Spearman’s correlation) or the duration
of RBD (r =− 0.217, P = .249, Spearman’s correlation).
ROC analysis of the early or delayed H/M ratio and
odor identiﬁcation showed an area under the curve of 0.96
(95% CI = 0.92−1.00,P = .000),0.99(95% CI = 0.96–1.00,
P = .000)and0.96(95% CI = 0.91–1.00,P = .000)foriRBD
(Figure 1(a)) and of 0.84 (95% CI = 0.74–0.94, P = .000),
0.88 (95% CI = 0.79–0.97, P = .000) and 0.98 (95% CI =
0.96–1.00, P = .000) for PD (Figure 1(b)).
For diﬀerentiating the iRBD patients from control sub-
jects, the sensitivity and speciﬁcity of the OSIT-J score with
ac u t - o ﬀ value at 8.5 were 90.0% and 83.3%, respectively;
those of the early H/M ratio with a cut-oﬀ value at 2.30
were 95.0% and 86.7%, respectively, and those of a delayed
H/M ratio with a cut-oﬀ value at 2.03 were 95.0% and
96.7%, respectively (Table 3). For diﬀerentiating PD patients
from control subjects, the sensitivity and speciﬁcity of the
OSIT-J score with a cut-oﬀ value at 8.5 were 90.0% and
92.1%, respectively; those of the early H/M ratio with a cut-
oﬀ value at 2.30 were 95.0% and 71.1%, respectively; and
those of the delayed H/M ratio with a cut-oﬀ value at 2.03
were 95.0% and 71.1%, respectively (Table 3). With optimal
cut-oﬀ values set at 2.03 for the delayed H/M ratio and at
8.5 for OSIT-J score for iRBD patients (Table 3,F i g u r e2),
identiﬁcation of iRBD was conﬁrmed in 23 (76.7%) patients
in the iRBD group through abnormal results of both of theseParkinson’s Disease 5
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Figure 2: The relation between the OSIT-J score and the delayed
H/M ratio of 123I-MIBG uptake in patients with iRBD (the red
circle), PD (the green square), and controls (the blue triangle).
Broken line (vertical): cut-oﬀ value set at 8.5 by OSIT-J to distin-
guish between iRBD or PD and controls. Broken line (horizontal):
cut-oﬀ value set at 2.03 by 123I-MIBG to distinguish between
iRBD or PD and controls. OSIT-J: Odor Stick Identiﬁcation
Test for Japanese; H/M: heart-to-mediastinum; 123I-MIBG:123I-
metaiodobenzylguanidine; OSAS: obstructive sleep apnea syn-
drome; iRBD: idiopathic rapid eye movement behavior disorder;
PD: Parkinson’s disease.
tests. Optimal cut-oﬀvalueswere set at 2.03for delayedH/M
ratio and at 8.5 for OSIT-J score for PD patients (Table 3,
Figure 2); as a result, 25 (65.8%) were conﬁrmed through
abnormal results of both of these tests to have PD. However,
results of both of these tests were normal in the control
group.
4.Discussion
In this study, the olfactory dysfunction and reduced cardiac
123I-MIBG uptake that were found in most iRBD patients
share similarities with those described in PD. Moreover,
delayed cardiac 123I-MIBG uptake was more severe in the
i R B Dg r o u pt h a ni nt h eP Dg r o u p( F i g u r e1(a))w h i l e
reducedodoridentiﬁcationwasmoresevereinthosewithPD
than with iRBD (Figure1(b)). Also, the degree of olfactory
identiﬁcation impairment correlated signiﬁcantly with the
degree of delayed cardiac 123I-MIBG uptake only in the
PD group. Age, sex, and delayed cardiac 123I-MIBG uptake
were signiﬁcant factors with regard to PD patients in the
model using the OSIT-J score. The degree of reduction of
MIBG uptake does not match the degree of reduction in
odor identiﬁcation in iRBD patients but does match in PD
patients. Results of a recent study indicated that the cardiac
sympathetic nervous system might degenerate in parallel
with the olfactory system in patients with early PD and that
thesetwosystems might degenerateatdiﬀerentratesofspeed
in advanced PD [16].
4.1. Cardiac Sympathetic Denervation Is Related to Lewy Body
Pathology. There is evidence that 123I-MIBG cardiac uptake
is markedly reduced in patients with Lewy body diseases
such as PD, dementia with Lewy bodies (DLB), and pure
autonomic failure (PAF) [17–19]. In was reported that car-
diac 123I-MIBG imaging could distinguish between clinically
diagnosed DLB and Alzheimer’s disease (AD) with high
levels of sensitivity and speciﬁcity [19]. Interestingly, patho-
logicalﬁndings occureveninpatientswith DLBwho haveno
parkinsonism. Since PAF patients do not have parkinsonism
or decreased striatal dopaminergic innervation and since
cardiac noradrenergic denervation occurs in both diseases,
the pathogenetic mechanisms of cardiac noradrenergic den-
ervation in Lewy body diseases diﬀer from those producing
parkinsonism and nigrostriatal dopaminergic denervation
[8]. As pathological evidence [20–22], it has been proven
that the Lewy body is present in cardiac sympathetic nerve
postganglionic ﬁbers and it has been suggested that Lewy
body-related pathologypotentiallycausesseveredenervation
and reduced 123I-MIBG uptake in the cardiac postganglionic
sympathetic nerve. The reduction in 123I-MIBG uptake in
sympatheticterminalswasobservedincaseswithearly-phase
PD and incidental Lewy body disease (ILBD) irrespective
of the presence or absence of remarkable autonomic nerve
injury [17].
4.2. Olfactory Dysfunction Is Related to Lewy Body Pathol-
ogy. Olfactory disturbance is present in most PD or PAF
cases [8, 23, 24]. The deﬁcit in olfaction in PD contrasts
with previous reports of preserved or only mildly reduced
olfaction in patients with atypical parkinsonism such as a
tauopathy or multiple system atrophy [25, 26]. In dementia
patients, neuropathologic studies reported neuronal alter-
ations in several subcortical structures such as the olfactory
tract/bulb, anterior olfactory nucleus, orbito-frontal cortex,
hippocampus, and amygdala in the olfactory system [27].
Olfactory abnormalities have been reported in AD, but
anosmia appears to be common in DLB but not in pure
AD [28]. Interestingly, a Lewy body variant of AD had an
increased frequency of anosmia compared with “pure” AD
[29]. Furthermore, olfactory impairment is more marked
in patients with mild dementia with Lewy bodies than in
those with mild AD [30]. In addition to reduced odor
identiﬁcation prior to the onset of PD, olfactory dysfunction
also has been frequently recognized in patients with ILBD
[31]. Also, neuropathological olfactory bulb alpha-synclein
has high speciﬁcity and sensitivity for Lewy body formation
in conﬁrmed cases of PD and DLB [32]. On the basis of
pathological studies of a large number of autopsy cases,
Braak et al. proposed a hypothesis as to the onset and
advancement pattern of PD in that the disease developed
from the medulla and olfactory bulb and extended to6 Parkinson’s Disease
the pons and substantia nigra (SN) [33]. In the Honolulu-
Asia Aging Study on Japanese Americans, 2,267 males with-
out PD and dementia at the time of olfaction testing were
followed up and signiﬁcantly more subjects who developed
olfactory dysfunction in the ﬁrst 4-year follow-up period
also developed PD [34]. Haehner’s study was to clinically
follow up patients with idiopathic hyposmia to determine
the percentage of patients who developed idiopathic PD
after a 4-year interval [35]. In Ponsen’s prospective study
involving ﬁrst-degree relatives of PD patients, a low score
on three olfactory processing tasks was associated with an
increased risk of developing PD within 5 years [36]. The
point of view that reduced odor identiﬁcation is manifested
at the very beginning of the development of PD has been
supported. These reports indicate that the rhinencephalon
may be an area of selective vulnerability for α-synuclein
accumulation [37] and iRBD that develops in middle age
or older progresses mostly to Lewy body diseases among
synucleinopathies such as PD and DLB, which have some
pathological features in common.
4.3. RBD and Relevance to Lewy Body Pathology. Men over
the age of 50 years who have iRBD are at very high risk
for future PD or DLB several years after the onset of RBD
[38,39].Neuropathologicstudiesatautopsyofcasesthathad
been diagnosed with RBD while alive showed that every case
had Lewy bodies [6]. For example, cognitive abnormalities
appeared 15 years after the onset of RBD and probable DLB
was diagnosed, and eventually the presence of Lewy bodies
was conﬁrmed pathologically [40]. In PD, approximately
60% of the nigrostriatal neurons of the substantia nigra are
degenerated before patients fulﬁll the clinical criteria of PD
[41]. In some cases of PD, the patient appears to develop
cortical disease before the motor sign of “stage 3” disease,
whereas, iRBD patients with ILBD could be diagnosed after
long-standing disease with noevidenceofmotororcognitive
abnormalities [3, 4]. If progression of syncleinopathies is
not universal, it is essential to understand the reason. Since
a variety of symptoms of PD and disorders resembling PD
have been elucidated,Langston [42]p r o p o s e da“ P a r k i n s o n ’ s
complex” because parkinsonism would represent only the
tip of the iceberg as typically viewed by both clinicians and
researchers. However, when the disease process is measured
by neuronal degeneration, the presence of Lewy bodies
and neuritic pathology are widespread in the central and
peripheral nervous systems. From this point of view, iRBD
can be positioned as an earlier preclinical stage of PD or
DLB, or a variant of Lewy body-related α-synucleinopathies.
To gain such an understanding, it is necessary to extract a
group with abnormalities in a combination of markers from
among iRBD patients and provide follow up, considering
the possibility that some patients in that group may develop
neurodegenerative disease. These steps may help elucidate
the possibility that iRBD is the spectrum of manifestations
or a subtype of Lewy body-related α-synucleinopathies.
In conclusion, reduced cardiac 123I-MIBG uptake may be
more closely associated with iRBD than olfactory impair-
ment. Moreover, odor identiﬁcation impairment or cardiac
sympathetic function assessed by cardiac 123I-MIBG uptake
and the nigrostriatal dopaminergic function would occur
and progress independently in iRBD patients or PD patients.
Limitations of this study include the small number of
OSAS patients that comprise the control group. Untreated
sleep apnea syndrome may be associated with physical
movements during sleep [1], and, therefore, it is important
to ﬁrst diﬀerentiatebetweenthose withiRBDandOSASwith
abnormal sleep behavior. A second limitation is that more
than 80% of patients presenting at sleep centers with iRBD
are men [1, 3, 39] so that the male-to-female ratio was not
matched in the iRBD, PD, and control groups.
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